PLoS ONE (Jan 2024)

AM-18002, a derivative of natural anmindenol A, enhances radiosensitivity in mouse breast cancer cells.

  • Da-Young Eum,
  • Myeonggyo Jeong,
  • Soon-Yong Park,
  • Jisu Kim,
  • Yunho Jin,
  • Jeyun Jo,
  • Jae-Woong Shim,
  • Seoung Rak Lee,
  • Seong-Joon Park,
  • Kyu Heo,
  • Hwayoung Yun,
  • Yoo-Jin Choi

DOI
https://doi.org/10.1371/journal.pone.0296989
Journal volume & issue
Vol. 19, no. 4
p. e0296989

Abstract

Read online

Natural anmindenol A isolated from the marine-derived bacteria Streptomyces sp. caused potent inhibition of inducible nitric oxide synthase without any significant cytotoxicity. This compound consists of a structurally unique 3,10-dialkylbenzofulvene skeleton. We previously synthesized and screened the novel derivatives of anmindenol A and identified AM-18002, an anmindenol A derivative, as a promising anticancer agent. The combination of AM-18002 and ionizing radiation (IR) improved anticancer effects, which were exerted by promoting apoptosis and inhibiting the proliferation of FM3A mouse breast cancer cells. AM-18002 increased the production of reactive oxygen species (ROS) and was more effective in inducing DNA damage. AM-18002 treatment was found to inhibit the expansion of myeloid-derived suppressor cells (MDSC), cancer cell migration and invasion, and STAT3 phosphorylation. The AM-18002 and IR combination synergistically induced cancer cell death, and AM-18002 acted as a potent anticancer agent by increasing ROS generation and blocking MDSC-mediated STAT3 activation in breast cancer cells.